Detalhe da pesquisa
1.
Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10.
J Immunol
; 198(10): 3809-3814, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28389592